News

A novel computational tool has been used to identify a metabolic weakness in acute myeloid leukemia, offering a new drug target.

Researchers at St. Jude built a machine learning model to predict which protein regions drive cancer-linked condensates. Testing intrinsically disordered regions from fusion oncoproteins, they found only 12% of human regions form droplets.

Researchers have discovered that the microbial metabolite TMA acts as a natural IRAK4 inhibitor, blocking inflammation and improving insulin sensitivity. This unveils a potential drug target and microbiome-driven strategy to treat type 2 diabetes.

A Karolinska Institutet study of nearly 400 patients shows that a lower dose of ipilimumab in combination immunotherapy for advanced melanoma leads to better tumor response, longer survival and fewer side effects compared to the traditional regimen.

Cornell researchers used an engineered rabies virus to trace how psilocybin reshapes neural circuits, weakening cortical feedback loops linked to rumination and strengthening the link between perception and action.

Biotech and pharma greenhouse gas emissions are falling – but is current progress fast enough? Discover My Green Lab’s Impact Report.

Researchers at the Max Planck Institute found that pregnant mice eating low-fat diets but exposed to fatty food odors produced offspring prone to obesity and insulin resistance. The odors altered neural circuits tied to hunger and reward.

KAIST researchers have developed a method that attaches DNA fragments to mRNA to slow the onset of protein production, reducing dangerous spikes linked to side effects and enabling personalized, safer mRNA therapies.

MIT researchers have synthesized verticillin A, a complex fungal compound discovered more than 50 years ago and long recognized for its anticancer potential. The compound’s fragile structure and precise stereochemistry make it difficult to produce.

A Phase 3 trial found that combining eflornithine with lomustine significantly improved survival for patients with recurrent grade 3 IDH-mutant astrocytoma, extending life by nearly a year compared with standard therapy.